Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125610501 | 12561050 | 1 | I | 20150610 | 20160706 | 20160715 | 20160715 | EXP | JP-BAYER-2016-134060 | BAYER | NAGAO M, NISHIOKA Y, FUJIMOTO K, FUKUDA H, MASAKI S, KUMAHARA K ET.AL.. CASE OF CR1-5. THE 52ND ANNUAL MEETING OF LIVER CANCER STUDY GROUP OF JAPAN. 2016;2016.7.1,2:209 | 70.00 | YR | E | M | Y | 0.00000 | 20160715 | MD | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125610501 | 12561050 | 1 | PS | NEXAVAR | SORAFENIB | 1 | Oral | DAILY DOSE 400 MG | 21923 | 400 | MG | FILM-COATED TABLET |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125610501 | 12561050 | 1 | Hepatocellular carcinoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125610501 | 12561050 | DE |
125610501 | 12561050 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125610501 | 12561050 | Diarrhoea | |
125610501 | 12561050 | Hepatocellular carcinoma | |
125610501 | 12561050 | Malaise | |
125610501 | 12561050 | Varices oesophageal |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125610501 | 12561050 | 1 | 20150602 | 20150727 | 0 |